Taxotere, Docetaxel
Taxotere, Docetaxel Newswire (Page 7)

Taxotere, Docetaxel Newswire (Page 7)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 7)

Results 121 - 140 of 1,089 in Taxotere, Docetaxel (generic)

  1. Pharmacy selling cancer drugs at heavy discount openedRead the original story

    Nov 15, 2015 | Newkerala.com

    New Delhi, Nov 15 : Union Health Minister J.P. Nadda on Sunday inaugurated India's first retail facility at AIIMS to provide drugs for cancer and cardiovascular diseases at highly discounted rates. The pharmacy named AMRIT -- Affordable Medicines and Reliable Implants for Treatment -- will have 202 drugs of cancer and cardiovascular diseases where the price is going to be reduced on an average by 60 to 90 percent.

    Comment?

  2. Drugs for cancer, cardiovascular diseases set to get cheaperRead the original story w/Photo

    Nov 14, 2015 | The Indian Express

    The Indian government will launch a programme to provide drugs for cancer and cardiovascular diseases at affordable rates, Health Minister J P Nadda is slated to announce Sunday. Under the scheme, drugs will be sold at a fraction of the market price.

    Comment?

  3. Celator Pharmaceuticals, Inc. Presents Positive Results From R&D ProgramsRead the original story

    Nov 9, 2015 | BioSpace

    CombiPlex is Celator's proprietary technology that uses nano-scale drug carriers to ensure the optimal ratio of anticancer drugs are simultaneously delivered and selectively exposed to tumor cells for prolonged periods of time while reducing drug exposure and toxicity to normal tissues. The technology addresses difficulties often experienced with conventional MTA combination regimens, where significant toxicities and/or incomplete target inhibition can lead to sub-optimal patient outcomes.

    Comment?

  4. BIND Therapeutics Presents Data Demonstrating Ability Of Accurins To...Read the original story

    Nov 8, 2015 | BioSpace

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurinsa , today reported data demonstrating the efficacy and tolerability of BIND's Accurin platform with multiple anti-cancer agents. These data, which were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston, November 5-9, 2015, describe the ability of Accurins to control the biodistribution of therapeutic payloads across multiple active anti-cancer agents, pathways and targets, which results in either improved efficacy, tolerability or both.

    Comment?

  5. DRP(TM) enables Irofulven clinical trial in prostate cancerRead the original story w/Photo

    Nov 8, 2015 | GlobeNewswire

    Hoersholm, Denmark; November 8 th , 2015 - Medical Prognosis Institute A/S has in collaboration with Oncology Venture AB, Denmark; Lanthern Pharma Inc., USA; and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, have published a poster under the title: "A two stage prospective clinical trial with irofulven treatment targeting a selected subgroup of castration- and docetaxel resistant prostate cancer patients., at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics announcing in Boston announcing the use of the DRP technology for a planned prospective trial with Irofulven treatment targeting a selected subgroup of castration and docetaxel resistant prostate cancer patients.

    Comment?

  6. iTeos Therapeutics Announces Appointment of Dr. Jean-Pierre Bizzari to...Read the original story

    Nov 6, 2015 | PRWeb

    Dr. Bizzari adds further depth to iTeos' board by bringing knowledge and experience gained through a long clinical and operational career for oncology therapeutics. iTeos Therapeutics SA announced today the appointment of Dr. Jean-Pierre Bizzari to the company's board of directors.

    Comment?

  7. Cerulean Pharma Receives Consensus Recommendation of "Buy" from AnalystsRead the original story

    Nov 5, 2015 | AmericanBankingNews.com

    Cerulean Pharma has earned a consensus rating of "Buy" from the seven research firms that are currently covering the company, Marketbeat.com reports . One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company.

    Comment?

  8. Celator Pharmaceuticals, Inc. To Report Third Quarter 2015 Financial Results On November 12, 2015Read the original story

    Nov 4, 2015 | BioSpace

    To participate in the conference call, please dial 303-6316 or 521-5176 and refer to conference ID 75399779. The live webcast of the call can be accessed in the Investors section of the Company's website at www.celatorpharma.com .

    Comment?

  9. Oppenheimer Brokers Boosts Earnings Estimates for BIND TherapeuticsRead the original story w/Photo

    Nov 5, 2015 | AmericanBankingNews.com

    Research analysts at Oppenheimer increased their Q4 2015 EPS estimates for BIND Therapeutics in a report issued on Tuesday, Zacks reports. Oppenheimer analyst C. Marai now expects that the brokerage will post earnings per share of for the quarter, up from their prior forecast of .

    Comment?

  10. Brokers Offer Predictions for BIND Therapeutics' Q4 2016 EarningsRead the original story w/Photo

    Nov 4, 2015 | AmericanBankingNews.com

    Oppenheimer issued their Q4 2016 EPS estimates for shares of BIND Therapeutics in a report released on Tuesday, Zacks reports. Oppenheimer analyst C. Marai anticipates that the brokerage will post earnings per share of for the quarter.

    Comment?

  11. Research Analysts Issue Forecasts for BIND Therapeutics' Q3 2016 EarningsRead the original story w/Photo

    Nov 4, 2015 | AmericanBankingNews.com

    Equities researchers at Oppenheimer issued their Q3 2016 earnings per share estimates for BIND Therapeutics in a research note issued to investors on Tuesday, Zacks reports. Oppenheimer analyst C. Marai expects that the brokerage will earn per share for the quarter.

    Comment?

  12. BIND Therapeutics (BIND) Forecasted to Post Q1 2016 Earnings of ($0.58) Per ShareRead the original story w/Photo

    Nov 4, 2015 | AmericanBankingNews.com

    Investment analysts at Oppenheimer issued their Q1 2016 earnings per share estimates for shares of BIND Therapeutics in a research note issued on Tuesday, according to Zacks Investment Research . Oppenheimer analyst C. Marai forecasts that the firm will earn per share for the quarter.

    Comment?

  13. Endocyte, Inc. Reports Third Quarter 2015 Financial Results And...Read the original story

    Nov 3, 2015 | BioSpace

    Endocyte, Inc. , a leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy, today announced financial results for the third quarter ending Sept. 30, 2015, and provided a clinical update.

    Comment?

  14. Merck KGaA, Darmstadt, Germany, And Pfizer Announce Initiation Of...Read the original story

    Nov 3, 2015 | BioSpace

    Merck KGaA And Pfizer Announce Initiation Of Phase III First-Line Trial Of Avelumab In Patients With Recurrent Or Stage IV Non-Small Cell Lung Cancer Trial marks second Phase III study of avelumab in non-small cell lung cancer initiated by Merck and Pfizer in just over six months Primary endpoint is progression-free survival in previously untreated patients with recurrent or Stage IV programmed death-ligand 1 positive NSCLC Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naA ve advanced NSCLC setting.

    Comment?

  15. Boehringer Ingelheim Initiates Pivotal Programme For Novel...Read the original story

    Nov 2, 2015 | BioSpace

    Boehringer Ingelheim today announced at the BIO-EuropeA conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and safety of BI 1482694 in patients with T790M mutation-positive non-small cell lung cancer , whose tumours stopped responding to currently available epidermal growth factor receptor directed therapies. The primary endpoint of this trial, which is the first in a broad clinical development programme for BI 1482694, is objective response rate .

    Comment?

  16. Why reform needs to start at cancer careRead the original story w/Photo

    Oct 29, 2015 | Kevin, M.D.

    Recently, the clinically positive results from the CLEOPATRA oncology trial were released, showing that pertuzumab, when added to docetaxel and trastuzumab as first-line chemotherapy, produces an average survival benefit of 15.7 months in HER2 positive breast cancer patients. That good news notwithstanding, the authors calculated that Genentech's price for adding pertuzumab to gain one quality adjusted life year is a breathtaking $713,219.

    Comment?

  17. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumoursRead the original story

    Oct 29, 2015 | British Journal of Cancer

    Presented, in part, at the European Society for Medical Oncology congress, 28 September-02 October 2012, Vienna, Austria. Abstract No.

    Comment?

  18. Merck & Co.'s Pembrolizumab Meets Primary Goal in Mid-Stage StudyRead the original story

    Oct 27, 2015 | BioSpace

    Merck's Pembrolizumab Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 KIRKLAND, QC , Oct. 28, 2015 /CNW Telbec/ - Merck , known as MSD outside Canada and the United States , today announced topline results from the KEYNOTE-010 study of pembrolizumab in advanced non-small-cell lung cancer demonstrating that the trial met its primary objective. KEYNOTE-010 is a randomized, pivotal Phase 2/3 trial comparing two doses of pembrolizumab , to docetaxel, a commonly used chemotherapy.

    Comment?

  19. Merck's Keytruda extends survival in lung cancer studyRead the original story w/Photo

    Oct 26, 2015 | Reuters

    Merck & Co's approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease. The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer , the most common form of lung cancer.

    Comment?

  20. Merck & Co.??'s KEYTRUDA (pembrolizumab) Shows Superior Overall...Read the original story

    Oct 25, 2015 | BioSpace

    Merck , known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDAA in advanced non-small-cell lung cancer demonstrating that the trial met its primary objective. KEYNOTE-010 is a randomized, pivotal Phase 2/3 trial comparing two doses of KEYTRUDA , to docetaxel, a commonly used chemotherapy.

    Comment?